Citations 43
Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.
Gounder, Mrinal M. , Somaiah, Neeta , Attia, Steven , Chawla, Sant P. , Villalobos, Víctor M. , Riedel, Richard F. , Wagner, Andrew J. , Mudenda, Boyd, Sadanowicz, Mara , Shah, Jatin J., Shacham, Sharon, Kauffman, Michael , Razak, Albiruni Ryan Abdul, Riedel, Richard F , Chmielowski, Bartosz , Burgess, Melissa , Schwartz, Gary K. , Mehren, Margaret von , Choy, Edwin , Verma, Shailendra , Li, Lingling
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11512-11512
A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.
Riedel, Richard F. , Lu, Yao , Attia, Steven , Ganjoo, Kristen N. , Livingston, Michael B. , Ward, John Harris, Rushing, Daniel A., Okuno, Scott H. , Keedy, Vicki L. , Ryan, Christopher W. , Maki, Robert G. , Maki, Robert G , Riedel, Richard F , Ballman, Karla V. , Loggers, Elizabeth T , Chow, Warren , Wright, Jennifer , Reed, Damon R. , Liebner, David A. , Mascarenhas, Leo , Davis, Lara E. , Reinke, Denise K.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11505-11505
TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.
Ravi, Vinod , Chawla, Sant P. , Attia, Steven , Riedel, Richard F. , Thornton, Katherine A., Mallick, Atrayee Basu , Liu, Lingyun , Alvarez, Delia, Theuer, Charles P. , Tap, William D. , Jones, Robin L. , Maki, Robert G. , Maki, Robert G , Riedel, Richard F , Jones, Robin L , Brohl, Andrew S. , Liebner, David A. , Mehta, Cyrus R. , Robinson, Steven I. , Penel, Nicolas , Stacchiotti, Silvia
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS11590-TPS11590